Search

Background: This study aims to study the predictors and the pattern of adverse drug reactions to Covishield vaccine which is being used in the mass vaccination program of the Government of India. Methods: This cross-sectional questionnaire-based study was conducted among the dentists working as faculty in four different tertiary care centers in Jaipur city. A prevalidated questionnaire was circulated through E-mail/social media groups to all the participants. Results: A total of 574 participants fulfilled the questionnaire platform; however, six had been excluded from the study due to incompletely filled questionnaires. The remaining 568 were enrolled for the final analysis. About 296 (52.11%) were male and 272 (47.89%) were female. About 52.8% were in the age group of 31–49 years. About 87.32% of the enrolled participants had received both doses of Covishield. Most common postvaccination symptoms were fever (n = 145), local pain at injection site (n = 123), tenderness at injection site (n = 117), and fatigue (n = 91). Female gender, presence of comorbid diseases, and past coronavirus disease-19 infection were statistically significant risk factors for having adverse reactions post vaccination, P = 0.02, 0.043, and 0.0002, respectively. Conclusions: The data suggest that Covishield is well tolerated in the Indian population. Fever, local pain, tenderness at injection site, and fatigue are few commonly reported side effects. All the side effects were mild to moderate in terms of severity.

Objectives: Quality of life (QOL) is a valuable prognostic indicator of survival in cancer patients. It further aids the health-care professionals to cater to patient needs. This study aimed to estimate longitudinally the changes in the QOL of oral cancer patients in early and late stages and receiving chemotherapy treatment. Materials and Methods: This was a prospective observational study conducted with 400 oral cancer patients receiving chemotherapy treatment at a government tertiary care cancer hospital in Jaipur city. QOL for each patient was measured before treatment, after 6 months, and 1 year posttreatment using the instrument Functional Assessment of Cancer Therapy-Head and Neck version 4. Statistical analysis was conducted with IBM Statistical Package for the Social Sciences for Windows version 17.0 software (IBM Corp., Armonk, NY, USA). For all the analyses, P < 0.05 was considered statistically significant. Results: A statistically significant difference in the mean score for physical (P < 0.0001), social (P < 0.0001), and functional (P = 0.001) well-being was recorded for early- and late-stage cancer patients at baseline. Only emotional (0.03) and social (0.04) well-being showed a significant improvement for late-stage cancer patients in contrast to early-stage patients where all QOL subscores improved longitudinally. Conclusion: Early-stage disease is associated with better QOL. Chemotherapy treatment could improve only emotional and social well-being parameters in late-stage disease patients. QOL studies can be fruitful clinical endpoint and should be inculcated in the framework of various tertiary care centers.